| Revenue growth | 31% YoY growth to INR 1,897.5 Mn. |
|---|---|
| Margins | EBITDA margin dropped to 25% from 35.6% YoY. |
| Demand visibility | Steady demand seen in LATAM and Europe for ADHD products. |
Growth
Revenue grew 31% YoY. However, EBITDA declined 8% and PAT fell 31% YoY due to higher operating expenses.
Outlook
Capacity expansion with new production blocks at Lote and Ambernath; targeting 3-4 new product launches annually.
Risks
Significant margin contraction (EBITDA margin down 1,063 bps YoY) and increased cost of goods sold.
Last quarter's promises, checked
Delivered
- Guided ~20% FY26 revenue growth → delivered 18.9% (~INR 828 Cr) (= BEAT)
- Guided 33%-35% EBITDA margin → delivered 35.5% (= BEAT)
- Guided 3-4 new product launches annually → delivered 4 launches in FY26 (= BEAT)
Partly delivered
- Guided INR 1,000 Cr revenue by FY27 → Q1 FY27 at INR 189.75 Cr (requires steep ramp-up) (= PARTIAL)
- Guided H2 FY27 launch for contrast media → development ongoing for enhanced economics (= PARTIAL)
Missed
- Guided 33%-35% EBITDA margin maintenance → delivered 25% in Q1 FY27 (= MISS)
Investor Presentation filed with NSE, NSE: SUPRIYA. Summary written with AI assistance from the document.
Supriya Lifescience Ltd: key numbers
- Share price
- ₹985.20
- Market cap
- ₹7,929 Cr
- Revenue (annual)
- ₹827.9 Cr
- Net profit (annual)
- ₹209.1 Cr
- P/E (TTM)
- 40.0×Sector 50.4×
- Promoter holding
- 68.30%+0.00% QoQ
- FII holding
- 6.18%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Supriya Lifescience Ltd
All →Supriya Lifescience Annual General Meeting
Supriya Lifescience Limited conducted its 18th Annual General Meeting on September 24, 2026. All resolutions proposed in the meeting were passed with the requisite majority.
Supriya Lifescience Legal & Regulatory
Bombay High Court ordered provisional release of 200 kg Ketamine Hydrochloride consignment subject to ₹0.72 Crore deposit. Criminal and NDPS proceedings continue.
- Value
- ₹0.72 Cr
Supriya Lifescience Results Correction
Supriya Lifescience explained missing segment details in its Q2 FY27 quick results filing. The omission was a technical XBRL display error; the company operates in one segment.
Supriya Lifescience Other Announcement
The company informs exchanges that it has dispatched communication regarding the Annual Report web link to shareholders with unregistered email IDs.
Supriya Lifescience Legal & Regulatory
Supriya Lifescience Limited informed stock exchanges that there have been no new developments regarding ongoing judicial proceedings involving its General Manager.
Supriya Lifescience Earnings Call Transcript: Key Takeaways
Supriya Lifescience is pivoting to Finished Dosage Forms (FDF) and R&D-driven specialized therapies with a new dedicated manufacturing unit. Focus is on high-margin Anaesthetic, Anti-diabetic, and CNS portfolios.